Amazon is in the early phases of developing cancer vaccines in a collaboration with the Seattle-based Fred Hutchinson Cancer Centre.

The tech giant is collaborating on a study focussed on personalised vaccines for patients with melanoma or breast cancer that has metastasised to other parts of the body and has proven unresponsive to treatment.

The US-based study is currently preparing to enter phase one of an FDA-approved clinical trial for which it will recruit 20 test patients.

The study description states that the personalised neo-antigen peptide vaccine is a product which combines multiple patient-specific neo-antigens.

The vaccine may offer more focused and precise cancer treatments at a lower cost and may also prove to be a good alternative to chemotherapy, according to reporting by Business Insider.

The study began on June 9 and is set to be completed by November 2023.

National Technology has reached out to Amazon for further comment.

Share Story: